Tellgen(SZ:300642) Sou Hu Cai Jing·2025-07-22 10:10Company Overview - The company, Shanghai TuoJing Life Technology Co., Ltd., focuses on the research, production, and sales of in vitro diagnostic products under its own brand [1] - Main products include in vitro diagnostic reagents, instruments, and service revenue [1] - The company actively participates in various health-themed public welfare activities and has received multiple awards for social responsibility, including the "Social Public Welfare Award" from the China Cancer Foundation [1] Financial Performance - For Q1 2025, the company reported operating revenue of 74.89 million yuan, a year-on-year decrease of 19.53% [1] - Net profit for the same period was 471,700 yuan, showing a significant year-on-year increase of 110.51% [1] - The sales gross margin stood at 63.66% [1] Market Position - As of July 22, the company's stock closed at 16.33 yuan, down 3.14%, with a rolling price-to-earnings (PE) ratio of 67.21 times [1] - The total market capitalization is 2.655 billion yuan [1] - In comparison to the industry, the average PE ratio for the medical device sector is 53.47 times, with a median of 37.00 times, placing the company at the 92nd position in the industry ranking [1][2] Shareholder Information - As of March 31, 2025, the number of shareholders is 17,040, a decrease of 590 from the previous count [1] - The average market value of shares held by each shareholder is 352,800 yuan, with an average holding of 27,600 shares [1]